News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerus Corporation (CERS) Submits the First of Three Modules in the Premarket Approval (PMA) Application Process for INTERCEPT Platelets


10/1/2013 10:49:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has submitted the first of three modules for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for platelets.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES